[go: up one dir, main page]

HUP9904516A2 - Oldható béta-limfotoxin receptorok, anti-limfotoxin receptor antitestek és anti-limfotoxin ligandum antitestek mint gyógyászati szerek immunológiai betegségek kezelésére - Google Patents

Oldható béta-limfotoxin receptorok, anti-limfotoxin receptor antitestek és anti-limfotoxin ligandum antitestek mint gyógyászati szerek immunológiai betegségek kezelésére

Info

Publication number
HUP9904516A2
HUP9904516A2 HU9904516A HUP9904516A HUP9904516A2 HU P9904516 A2 HUP9904516 A2 HU P9904516A2 HU 9904516 A HU9904516 A HU 9904516A HU P9904516 A HUP9904516 A HU P9904516A HU P9904516 A2 HUP9904516 A2 HU P9904516A2
Authority
HU
Hungary
Prior art keywords
lymphotoxin
receptor
antibodies
treatment
soluble
Prior art date
Application number
HU9904516A
Other languages
English (en)
Inventor
Jeffrey Browning
Paula Susan Hochman
Fabienne Mackay
Paul D. Rennert
Original Assignee
Biogen, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen, Inc. filed Critical Biogen, Inc.
Publication of HUP9904516A2 publication Critical patent/HUP9904516A2/hu
Publication of HUP9904516A3 publication Critical patent/HUP9904516A3/hu
Publication of HU226467B1 publication Critical patent/HU226467B1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • AIDS & HIV (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A találmány tárgyát őlyan eljárásők képezik, amelyek módősítják ahűmőrális imműnválaszt a limfőtőxin-receptőr (LT--R) jelátvitelgátlása révén. A találmány az LT reakcióút gátlására szőlgáló blőkkőlószereket tartalmazó készítményekre is vőnatkőzik. Előnyös blőkkőlószerek a következők: ődlható limfőtőxinreceptőr, LT-receptőr elleniantitestek és LT ligandűm elleni antitestek. Az őldható hűmán LT-receptőrt a GenBank-ban lévő cDNS klónból kiindűlva, rekőmbinánstechnikákkal állítőtták elő, mégpedig hűmán imműnglőbűlin Fcfragmentűmmal fűziőnált főrmában. Az LT reakcióűtat blőkkőlógyógyszerkészítmények őlyan imműnőlógiai betegségek kezelésénélfejtenek ki jótékőny hatást, amelyeket antitest közvetítettimműnválaszők - főként abnőrmális vagy túlzőtt hűmőrális imműnválaszők- őkőznak. Ilyenek példáűl az aűtőimműn betegségek vagy atranszplantációhőz társűlt szövődmények. A találmány szerintgyógyszerkészítmény felhasználhatók fertőző betegségek - példáűl aHIV, illetve az AIDS - kezelésénél, előnyösen hagyőmányőskészítményekkel kőmbinálva. ŕ
HU9904516A 1996-10-25 1997-10-24 Soluble lymphotoxin-beta receptors and use of anti-lymphotoxin receptor antibodies for production of pharmaceutical compostions for the treatment of autoimmunological diseases HU226467B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2906096P 1996-10-25 1996-10-25
PCT/US1997/019436 WO1998017313A2 (en) 1996-10-25 1997-10-24 Soluble lymphotoxin-beta receptors, anti-lymphotoxin receptor antibodies, and anti-lymphotoxin ligand antibodies as therapeutic agents for the treatment of immunological diseases

Publications (3)

Publication Number Publication Date
HUP9904516A2 true HUP9904516A2 (hu) 2000-05-28
HUP9904516A3 HUP9904516A3 (en) 2002-09-30
HU226467B1 HU226467B1 (en) 2008-12-29

Family

ID=21847003

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9904516A HU226467B1 (en) 1996-10-25 1997-10-24 Soluble lymphotoxin-beta receptors and use of anti-lymphotoxin receptor antibodies for production of pharmaceutical compostions for the treatment of autoimmunological diseases

Country Status (26)

Country Link
EP (1) EP0954333B1 (hu)
JP (1) JP4299887B2 (hu)
KR (1) KR100584704B1 (hu)
CN (2) CN100382844C (hu)
AT (1) ATE331531T1 (hu)
AU (1) AU726357B2 (hu)
BG (1) BG63565B1 (hu)
BR (1) BR9712670A (hu)
CA (1) CA2269614A1 (hu)
CZ (1) CZ142899A3 (hu)
DE (1) DE69736244T2 (hu)
DK (1) DK0954333T3 (hu)
EA (1) EA002983B1 (hu)
EE (1) EE05213B1 (hu)
ES (1) ES2268727T3 (hu)
HK (1) HK1025500A1 (hu)
HU (1) HU226467B1 (hu)
IL (1) IL129527A (hu)
IS (1) IS5031A (hu)
NO (1) NO328540B1 (hu)
NZ (1) NZ335353A (hu)
PL (1) PL190617B1 (hu)
PT (1) PT954333E (hu)
SK (1) SK55399A3 (hu)
TR (1) TR199901636T2 (hu)
WO (1) WO1998017313A2 (hu)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925351A (en) 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
US7118742B2 (en) 1997-07-07 2006-10-10 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
US6140467A (en) * 1997-07-07 2000-10-31 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
US6998108B1 (en) 1997-07-07 2006-02-14 La Jolla Institute For Allergy And Immunology Antibodies to p30 polypeptides and methods making and using same
EP1119370B1 (en) * 1998-10-09 2006-06-14 Biogen Idec MA Inc. Reversal of viral-induced systemic shock and respiratory distress by blockade of the lymphotoxin beta pathway
TR200504220T2 (tr) * 1998-12-17 2007-04-24 Biogen Idec Ma Inc. Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem.
JP3822822B2 (ja) * 1999-06-28 2006-09-20 ビーエーエスエフ アクチェンゲゼルシャフト 腫瘍の成長を予防する方法
DE19939653A1 (de) * 1999-08-13 2001-02-22 Thomas Huenig Verwendung CD28 spezifischer monoklonaler Antikörper zur Herstellung einer pharmazeutischen Zusammensetzung
WO2001079496A2 (en) * 2000-03-13 2001-10-25 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
EP1674575B1 (en) * 2000-04-12 2010-10-06 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
AU2003303339A1 (en) * 2002-12-20 2004-07-22 Biogen Idec Ma Inc. Lymphotoxin beta receptor agents in combination with chemotherapeutic agents
PE20080980A1 (es) 2006-10-12 2008-09-02 Genentech Inc Anticuerpos anti-linfotoxina alfa
SG178002A1 (en) 2006-10-20 2012-02-28 Biogen Idec Inc Treatment of demyelinating disorders
US8338376B2 (en) 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
US20120070436A1 (en) * 2009-05-28 2012-03-22 Richard Lewis Easeman Antigen-binding proteins
EP3807401A1 (en) * 2018-06-15 2021-04-21 Universität Bern LIGANDS TO LIGHT OR ITS RECEPTOR LTßR FOR USE IN HAEMATOLOGIC MALIGNANCIES
KR102360196B1 (ko) 2019-10-30 2022-02-08 주식회사 친환경테크 다용도 시트 조성물

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69334224D1 (de) * 1992-12-04 2008-07-17 Biogen Idec Inc Lymphotoxin-beta, lymphotoxin-beta komplexe, pharmazeutische zubereitungen und therapeutische verwendungen davon
US5925351A (en) * 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease

Also Published As

Publication number Publication date
NO991926D0 (no) 1999-04-22
NO991926L (no) 1999-06-25
CN1237910A (zh) 1999-12-08
ATE331531T1 (de) 2006-07-15
JP4299887B2 (ja) 2009-07-22
EE05213B1 (et) 2009-10-15
IL129527A0 (en) 2000-02-29
BG103416A (en) 2000-01-31
NO328540B1 (no) 2010-03-15
BG63565B1 (bg) 2002-05-31
NZ335353A (en) 2000-09-29
EP0954333A2 (en) 1999-11-10
BR9712670A (pt) 1999-10-19
HU226467B1 (en) 2008-12-29
KR100584704B1 (ko) 2006-05-30
IL129527A (en) 2006-12-10
PL190617B1 (pl) 2005-12-30
TR199901636T2 (xx) 1999-09-21
CA2269614A1 (en) 1998-04-30
PT954333E (pt) 2006-10-31
KR20000052800A (ko) 2000-08-25
IS5031A (is) 1999-04-21
DE69736244D1 (de) 2006-08-10
WO1998017313A3 (en) 1998-07-30
EP0954333B1 (en) 2006-06-28
EA199900409A1 (ru) 2000-02-28
SK55399A3 (en) 2000-10-09
AU5089698A (en) 1998-05-15
HUP9904516A3 (en) 2002-09-30
EA002983B1 (ru) 2002-12-26
AU726357B2 (en) 2000-11-02
WO1998017313A2 (en) 1998-04-30
HK1025500A1 (en) 2000-11-17
EE9900146A (et) 1999-12-15
ES2268727T3 (es) 2007-03-16
JP2001502697A (ja) 2001-02-27
CN101239186A (zh) 2008-08-13
PL332972A1 (en) 1999-10-25
CZ142899A3 (cs) 1999-07-14
DE69736244T2 (de) 2007-05-31
DK0954333T3 (da) 2006-10-23
CN100382844C (zh) 2008-04-23

Similar Documents

Publication Publication Date Title
HUP9904516A2 (hu) Oldható béta-limfotoxin receptorok, anti-limfotoxin receptor antitestek és anti-limfotoxin ligandum antitestek mint gyógyászati szerek immunológiai betegségek kezelésére
Ahrends et al. The opposing roles of CD 4+ T cells in anti‐tumour immunity
Zou et al. Human glioma-induced immunosuppression involves soluble factor (s) that alters monocyte cytokine profile and surface markers
Alpan et al. The role of dendritic cells, B cells, and M cells in gut-oriented immune responses
Andersson et al. Intravenous immune globulin affects cytokine production in T lymphocytes and monocytesjmacrophages
Germann et al. Interleukin‐12/T cell stimulating factor, a cytokine with multiple effects on T helper type 1 (Th1) but not on Th2 cells
Bliss et al. IL-12, as an adjuvant, promotes a T helper 1 cell, but does not suppress a T helper 2 cell recall response.
Brandtzaeg Mucosal immunity in the female genital tract
Trinchieri et al. The role of interleukin 12 in the immune response, disease and therapy
Doe The intestinal immune system
Nagler-Anderson Tolerance and immunity in the intestinal immune system
AU1643692A (en) Use of cell surface receptor targeted molecules for the treatment of viral diseases
Colgan et al. IFN-gamma modulates CD1d surface expression on intestinal epithelia
Sartori et al. Interleukin-12: an immunoregulatory cytokine produced by B cells and antigen-presenting cells
Li et al. Cholera toxin B subunit binding to an antigen-presenting cell directly co-stimulates cytokine production from a T cell clone
NO970264L (no) Farmasöytiske blandinger omfattende et chimærisk TNF-bindende protein
Gärdby et al. Requirements for B7-CD28 costimulation in mucosal IgA responses: paradoxes observed in CTLA4-Hγ1 transgenic mice
Selvaraj et al. Anti‐VEGF antibody enhances the antitumor effect of CD40
Stein et al. Immune-based therapeutics: scientific rationale and the promising approaches to the treatment of the human immunodeficiency virus-infected individual
Specht et al. Prostaglandins, but not tumor‐derived IL‐10, shut down concomitant tumor‐specific CTL responses during murine plasmacytoma progression
Nagler-Anderson et al. Peripheral nonresponsiveness to orally administered soluble protein antigens
Ushio et al. IL-12 reverses established antigen-specific tolerance of contact sensitivity by affecting costimulatory molecules B7-1 (CD80) and B7-2 (CD86)
LAUNOIS et al. Setting in motion the immune mechanisms underlying genetically determined resistance and susceptibility to infection with Leishmania major
CO4820397A1 (es) TRATAMIENTO CONTRA EL ASMA CON TNFR -Ig
NO930798L (no) Fremgangsmaate og middel mot tumorer

Legal Events

Date Code Title Description
FH91 Appointment of a representative

Free format text: FORMER REPRESENTATIVE(S): RATHONYI ZOLTAN, S.B.G. & K. BUDAPESTI NEMZETKOEZI SZABADALMI IRODA, HU

Representative=s name: DR.LANG TIVADARNE S.B.G.& K.SZABADALMI UEGYVIV, HU

FH92 Termination of representative

Representative=s name: RATHONYI ZOLTAN, S.B.G. & K. BUDAPESTI NEMZETK, HU

HC9A Change of name, address

Owner name: BIOGEN IDEC MA INC., US

Free format text: FORMER OWNER(S): BIOGEN, INC., US

MM4A Lapse of definitive patent protection due to non-payment of fees